← All trials
NCT04150458
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Jan 31, 2030
- Completion date
- Jul 31, 2030
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- McGill UniversityLead sponsor
- McGill UniversityOverall official - principal investigator
- McGill UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.